These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 2668978)

  • 1. Double-blind, placebo-controlled, fixed dose trial of minaprine in patients with major depression.
    Amsterdam JD; Dunner DL; Fabre LF; Kiev A; Rush AJ; Goodman LI
    Pharmacopsychiatry; 1989 Jul; 22(4):137-43. PubMed ID: 2668978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minaprine and imipramine in the treatment of major depressive disorders. A comparative double-blind study.
    Bohacek N; Ravic M; Bizière K
    Drugs Exp Clin Res; 1987; 13(7):435-42. PubMed ID: 3308390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minaprine and dose response in depression. An investigation of two fixed doses of minaprine compared with imipramine.
    Montgomery SA; Baldwin DS; Priest RG; Steinert J; Patel A; Herrington RN; Livingston HM
    Pharmacopsychiatry; 1991 Sep; 24(5):168-74. PubMed ID: 1775522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet 3H-imipramine binding and response to minaprine in patients with major depression.
    Maj M; Mastronardi P; Palomba U; Romano M; Ventra C; Kemali D
    Pharmacopsychiatry; 1988 Mar; 21(2):101-3. PubMed ID: 3393597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind study of minaprine versus amitriptyline in major depression.
    Del Zompo M; Bernardi F; Burrai C; Bocchetta A
    Neuropsychobiology; 1990-1991; 24(2):79-83. PubMed ID: 2134115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Placebo-controlled trial of venlafaxine for the treatment of major depression.
    Schweizer E; Weise C; Clary C; Fox I; Rickels K
    J Clin Psychopharmacol; 1991 Aug; 11(4):233-6. PubMed ID: 1918421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the safety and efficacy of bupropion in depression.
    Halaris AE; Stern WC; Van Wyck Fleet J; Reno RM
    J Clin Psychiatry; 1983 May; 44(5 Pt 2):101-3. PubMed ID: 6406435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of placebo-controlled trials with bupropion.
    Zung WW
    J Clin Psychiatry; 1983 May; 44(5 Pt 2):104-14. PubMed ID: 6406436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.
    Septien-Velez L; Pitrosky B; Padmanabhan SK; Germain JM; Tourian KA
    Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venlafaxine in depressed outpatients.
    Khan A; Fabre LF; Rudolph R
    Psychopharmacol Bull; 1991; 27(2):141-4. PubMed ID: 1924660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind placebo-controlled study of fluvoxamine and imipramine in depression.
    Dominguez RA; Goldstein BJ; Jacobson AF; Steinbook RM
    J Clin Psychiatry; 1985 Mar; 46(3):84-7. PubMed ID: 3918993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients.
    Mendels J; Reimherr F; Marcus RN; Roberts DL; Francis RJ; Anton SF
    J Clin Psychiatry; 1995; 56 Suppl 6():30-6. PubMed ID: 7649971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bupropion in depression: a tri-center placebo-controlled study.
    Pitts WM; Fann WE; Halaris AE; Dressler DM; Sajadi C; Snyder S; Ilaria RL
    J Clin Psychiatry; 1983 May; 44(5 Pt 2):95-100. PubMed ID: 6406473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors that influence the outcome of placebo-controlled antidepressant clinical trials.
    Niklson IA; Reimitz PE; Sennef C
    Psychopharmacol Bull; 1997; 33(1):41-51. PubMed ID: 9133750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression.
    Bech P; Tanghøj P; Andersen HF; Overø K
    Psychopharmacology (Berl); 2002 Aug; 163(1):20-5. PubMed ID: 12185396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Milnacipran and pindolol: a randomized trial of reduction of antidepressant latency.
    Isaac MT; Isaac MB; Gallo F; Tournoux A
    Hum Psychopharmacol; 2003 Dec; 18(8):595-601. PubMed ID: 14696018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicentric double-blind study comparing efficacy and safety of minaprine and imipramine in dysthymic disorders.
    Salzmann E; Robin JL
    Neuropsychobiology; 1995; 31(2):68-75. PubMed ID: 7760988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder.
    Feighner J; Hendrickson G; Miller L; Stern W
    J Clin Psychopharmacol; 1986 Feb; 6(1):27-32. PubMed ID: 3081600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nefazodone: aspects of efficacy.
    Rickels K; Robinson DS; Schweizer E; Marcus RN; Roberts DL
    J Clin Psychiatry; 1995; 56 Suppl 6():43-6. PubMed ID: 7649973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.